PolyPeptide Group Expands Credit Facility to EUR 200M to Fund Strategic Plan Through 2028
PolyPeptide Group AG announced that it has expanded its existing credit facility to EUR 200 million in support of growth ambitions and progress toward doubling 2023 revenue by 2028. The Swedish-Belgian peptide CDMO is one of the four large dedicated peptide manufacturers — alongside Bachem, CordenPharma, and Sun Pharma's Hyderabad PolyPeptide platform — and has previously announced a EUR 100M expansion in Malmö plus large-scale SPPS production in Braine-l'Alleud, Belgium that started in late 2024. The credit move heads into TIDES USA 2026 (May 11–14, Boston), where capacity, GMP investment, and large-scale SPPS economics will dominate the panel agenda.